Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 628084, 6 pages
Research Article

Clear Cell Cancer of the Uterine Corpus: The Association of Clinicopathologic Parameters and Treatment on Disease Progression

1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208063, New Haven, CT 06520, USA
2Department of Pathology, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA
3Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520, USA

Received 5 August 2011; Revised 11 October 2011; Accepted 15 October 2011

Academic Editor: Richard T. Penson

Copyright © 2011 Joyce Varughese et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients ( 𝑛 = 8 0 ) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS ( 𝑃 = 0 . 0 2 ) but not PFS ( 𝑃 = 0 . 1 0 ). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.